Javier Cortes, MD, PhD | Authors

Articles

Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355

June 03, 2020

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.